The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced a major collaboration with US-based Regeneron Pharmaceuticals, highlighted by a US$40 million upfront payment and the development of next-generation radiopharmaceuticals for cancer treatment.
What did Telix Pharmaceuticals report?
- Entered a 50/50 global cost and profit-sharing agreement with Regeneron to co-develop radiopharmaceutical therapies targeting solid tumours.
- Receives a US$40 million upfront cash payment for four initial therapeutic programs, with the option for Regeneron to expand to four more programs.
- Potential to earn up to US$2.1 billion in development and commercial milestone payments plus low double-digit royalties if Telix opts out of co-funding any program.
- Joint development of diagnostic assets, with Telix leading commercialisation and Regeneron receiving a percentage of profits.
- Collaboration leverages Telix’s expertise in radiopharmaceuticals and Regeneron’s proprietary antibody platforms.
What else do investors need to know?
This collaboration brings together Telix’s strong track record in radiopharmaceutical manufacturing and Regeneron’s experience in antibody discovery and oncology. The combined expertise could help accelerate the development of innovative treatments for cancers with significant unmet needs, such as lung cancer.
The partnership also includes plans to create radio-diagnostic tools, supporting both targeted therapies and patient selection for optimal outcomes. Telix retains some flexibility to promote products and can choose its level of involvement for each program, potentially switching between co-funding or milestone- and royalty-based compensation.
What did Telix Pharmaceuticals management say?
Managing Director and Group CEO Christian Behrenbruch said:
The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients.
What’s next for Telix Pharmaceuticals?
Telix and Regeneron will begin work on the first four programs under their collaboration, initially focusing on solid tumour targets from Regeneron’s antibody pipeline. Further expansion is possible if milestones are met and both parties exercise their program options.
Telix’s ability to co-develop diagnostics and therapies with Regeneron could set the stage for new approaches in precision oncology while expanding its global reach and product portfolio. Investors will be watching for progress updates and future milestones as the partnership unfolds.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 44%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.
The post Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- GQG Partners share price in focus as Q1 FUM update reveals outflows
- Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal
- Champion Iron finalises acquisition of Norway’s Rana Gruber
- Brambles shares: Class action judgment update
- The a2 Milk Company lowers FY26 guidance amid supply chain challenges
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.